Weekly Rundown: Key Catalysts for Small-Cap Stocks (October 20–24)

From recent disclosures to corporate shifts, we’ve highlighted the top small-cap catalysts to watch. Here’s your weekly preview (October 20-24).

--

Companies Participating in LD Micro Main Event XIX

Hotel del Coronado | San Diego, California | October 19–21, 2025

Participating Companies:

• CXDO • FUFU • DHX • NTRP • ZENA • EPM • UCL • ODYS • WYY • PRTS • CTXR • CWD • BNZI • XHLD • TYGO • NXGL • LCUT • MNOV • CISO • AUUD • ELUT • CJMB • DGLY • ZDGE • KBSX • ISPR • ZBAO • LSTA • ALTO • MDBH

Companies Participating at the New to The Street “Meet the Companies” Accredited Investor Event

Hudson Yards, New York City | October 21–22, 2025

Participating Companies:

• SNYR • DVLT • RDZN • AREB

Companies Presenting at IDWeek 2025™

Atlanta, Georgia | October 19–22, 2025 | Georgia World Congress Center:

● TOVX will present new safety and pharmacokinetic data from its ongoing Phase 1b/2a trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant recipients for the prevention of acute graft-versus-host disease. The poster, titled “Safety and tolerability of SYN-004 in allogeneic HCT recipients receiving meropenem or piperacillin/tazobactam,” will be presented by Dr. Erik R. Dubberke of Washington University on Monday, October 20, from 12:15–1:30 p.m. EDT in Poster Hall B4-5.

● ITRM will host a Learning Lounge session titled “An Overview of Urinary Tract Infection in Adult Women: Focus on Oral Sulopenem” on Tuesday, October 21, at 1:15 p.m. EST, featuring Drs. Steven I. Aronin and Michael Dunne. The company will also present two posters: “Risk factors for treatment failure in patients with uncomplicated urinary tract infection” (Poster #P784, October 20) and “In vitro activity of sulopenem and comparator agents against U.S. Enterobacterales clinical isolates, SENTRY 2023” (Poster #P1208, October 21), both in Poster Hall B4-5.

● SPRO, in collaboration with GSK, will highlight new data on tebipenem pivoxil hydrobromide (Tebipenem Hbr), an investigational oral carbapenem for complicated urinary tract infections. The oral presentation, “Oral Tebipenem vs. IV Imipenem-Cilastatin in cUTI or Acute Pyelonephritis: Phase 3 PIVOT-PO Results,” will be delivered by Dr. David K. Hong on Monday, October 20, from 1:45–3:00 p.m. ET in Room B401-B402. Two supporting posters on tebipenem’s antibacterial spectrum and activity against Enterobacterales isolates will be presented on Tuesday, October 21, from 12:15–1:30 p.m. in Poster Hall B4-5.

● ARMP will present results from its Phase 2a randomized, double-blind trial evaluating the intravenous bacteriophage therapy AP-SA02 versus placebo in combination with best available antibiotic therapy in patients with complicated Staphylococcus aureus bacteremia. The oral presentation, delivered by Dr. Loren G. Miller of UCLA and Harbor-UCLA Medical Center, is titled “A Phase 2a Trial of AP-SA02 in S. aureus Bacteremia” and will take place on Wednesday, October 22, from 10:30–11:45 a.m. ET in Room B401-B402.

Companies Presenting at Chardan’s 9th Annual Genetic Medicines Conference

New York, NY | October 21, 2025

Participating Companies:

•TNYA • PRME • OCGN • PRQR • IRD • SNTI • IPSC

Companies Presenting at the H.C. Wainwright Liver Disease Virtual Conference

Virtual Event | October 21–22, 2025

Participating Companies (Company Overview Presentations):

• PRQR • MTVA • ALT

Companies Participating at the 2025 Maxim Growth Summit

The Hard Rock Hotel, New York City | October 22–23, 2025

Participating Companies:

• DEFT • OCGN • CTOR • CCLD • LUCD • AMPG • GANX • NXL • AYTU • CODX • BRTX • HCWB • AMIX • MYNZ • ZENA • ICCM • CERO • AZTR • ATOS • INMB • MDCX • DWTX • OSTX • URG • RDZN • GNSS • ZONE • KPRX

Companies Participating in the Planet MicroCap Showcase Conference

Arcadian Loft, Toronto | October 21–23, 2025

Participating Companies:

• UPXI • CTW • TYGO • HOVR • AYTU • PRSO • PLBY • ISPR • HITI

Companies Presenting at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Hynes Convention Center, Boston, Massachusetts | October 22–26, 2025:

● APRE will present two posters highlighting updated data from its clinical programs. The first, “Early safety and efficacy of APR-1051, a novel WEE1 inhibitor,” and the second, “Updated data from ABOYA-119: A Phase 1/2a trial of ATRN-119, a macrocyclic ATR inhibitor,” will both be featured in Poster Session B on Friday, October 24, 12:30–4:00 p.m. ET in Exhibit Hall D.

● PMVP will deliver an oral presentation and two posters on rezatapopt for TP53 Y220C-mutant solid tumors. The oral presentation, “Initial analysis of the pivotal PYNNACLE Phase 2 trial,” takes place Friday, October 24, 10:00–11:40 a.m. ET in Ballroom AB. Poster presentations include the same Phase 2 analysis (Friday, October 24, 12:30–4:00 p.m.) and “Natural history and prognostic value of TP53 Y220C mutation in advanced solid tumors” (Saturday, October 25, 12:30–4:00 p.m.) in Exhibit Hall D.

● RPTX will present initial safety, tolerability, and early efficacy data from its Phase 1 LIONS trial in a poster titled “Preliminary safety and antitumor activity of RP-1664, a first-in-class PLK4 inhibitor.” The presentation (Abstract LB-C002) will appear in Poster Session C on Saturday, October 25, 12:30–4:00 p.m. ET in Exhibit Hall D.

● BOLD will present new preclinical data in a poster titled “Synergistic oral combination of selective RNR inhibitor BBI-825 with CHK1 inhibitor BBI-355.” The poster (Abstract LB-A022) is part of Poster Session A on Thursday, October 23, 12:30–4:00 p.m. ET in Exhibit Hall D.

● ZNTL will feature four azenosertib posters covering Phase 1 results and ongoing studies in ovarian and HER2-positive cancers. Presentations include: “Results from the Phase 1 dose escalation and expansion study,” “Rationale for early-line use in cyclin E1-positive HGSOC,” and two “Trial in Progress” updates. Sessions take place Thursday–Friday, October 23–24, 12:30–4:00 p.m. ET in Exhibit Hall D.

● PYXS will present six posters showcasing preclinical and translational data on micvotabart pelidotin, an antibody-drug conjugate (ADC) targeting non-cellular EDB+FN. Topics include its binding properties, immune activation, combination potential with anti-PD-1 therapy, and multiplex immunofluorescence workflows. All posters will be presented during Poster Session A on Thursday, October 23, 12:30–4:00 p.m. ET in Exhibit Hall D.

● ATNM will share first-ever preclinical data from its ATNM-400 program in non-small cell lung cancer. The poster, “ATNM-400, a first-in-class Actinium-225 antibody radioconjugate, demonstrates potent anti-tumor activity and overcomes osimertinib resistance in lung cancer models,” will appear in Poster Session C on Saturday, October 25, 12:30–4:00 p.m. ET in Exhibit Hall D.

● GNPX will present a poster titled “Quaratusugene ozeplasmid mediated TUSC2 upregulation in EML4-ALK bearing NSCLC” at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics on October 25, 2025, during Poster Session C (12:30–4:00 p.m. ET).

Additional Companies with Material Events This Week:

● SES will unveil Molecular Universe 1.0 (MU-1), its latest and most complete battery material discovery software and service platform, at The Battery Show – North America on October 20, 2025.

● ENTX will present new clinical data from its Phase 2 trial of EB613 at the North American Menopause Society (NAMS) 2025 Annual Meeting, taking place October 21–25, 2025, in Orlando, Florida. This marks Entera’s first presentation at NAMS.

● FLNT will showcase updates on its partnership Rebuy Monetize powered by Fluent at the Rebuy Momentum Innovation Summit NYC on October 21, 2025, highlighting new merchant monetization opportunities.

● AGEN will host a virtual Stakeholder Briefing on October 21, 2025, at 4:00 p.m. ET, featuring updates on clinical progress and expanded international access for its immunotherapy combination botensilimab (BOT) and balstilimab (BAL). The event will be moderated by Garo Armen, PhD, and conclude with a live Q&A session.

● SLNH CTO Dip Patel will join the panel “Meeting Demand Growth: Onshoring Power for Next Gen Hyperscalers, AI, & Other Large Energy Customers” at Infocast’s Energy Independence Summit in Houston, TX, on October 21, 2025, from 1:45–2:30 p.m. CT.

● KLTO leadership will attend Longevity Biotech 2025 in Boston, MA, on October 22–23, 2025, at Wightman Mansion, joining discussions on next-generation longevity therapeutics with leaders across biotech, pharma, and academia.

● SPRC announced entry into a definitive asset and share purchase agreement to acquire a controlling interest in Miza III Ventures Inc. (TSXV:MIZA) and transfer certain pharmaceutical assets. The transaction, if completed, is expected to close on or around October 22, 2025, aligning with SciSparc’s strategy to expand shareholder value.

● BMR will exhibit at NAB Show New York on October 22–23, 2025, showcasing NVIDIA GPU-accelerated video workflows featuring RTX Video Super Resolution for real-time AI-powered 4K video enhancement.

● XRX will debut the Xerox IJP900 at PRINTING United 2025 in Orlando, Florida, from October 22–24, 2025, with live demonstrations at booth #4521 as part of the Xerox Production Ecosystem.

● ATNM will share preclinical data for its ATNM-400 program, a novel Actinium-225 radioconjugate for prostate cancer, at the 32nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat, held October 23–25, 2025, in Carlsbad, CA.

● SVRA will present two posters and one oral presentation at CHEST 2025 in Chicago, IL, from October 19–22, 2025, and will host a Learning Theatre titled “Advances in Autoimmune Pulmonary Alveolar Proteinosis.”

● SXTP will participate in a RedChip investor webinar with 60 Degrees Pharmaceuticals on October 22, 2025, at 4:15 p.m. ET, featuring CEO Geoffrey Dow, PhD.

● VTGN will present data on its pherine nasal spray PH80 at The Menopause Society 2025 Annual Meeting in Orlando, FL, on Thursday, October 23, 2025.

● IMUX will join H.C. Wainwright’s “HCW @ Home with Immunic” virtual fireside chat on October 23, 2025, at 11:00 a.m. ET, featuring Dr. Vitt and Jason Tardio, the company’s President and COO.

● SNAL will showcase its award-winning title “Above the Snow” at the Poznań Game Arena, October 24–26, 2025, revealing collaborations with brands Cortazu, Fjordfiesta, and Heywood, and offering a playable demo at Pavilion 5, Sector B.

● ZENA will attend Stocktoberfest Presented by StockTwits, held October 20–22, 2025, at the Hotel del Coronado in Coronado, CA, connecting traders, creators, and investors around digital storytelling and market trends.

● FEMY will exhibit at the American Society for Reproductive Medicine (ASRM) 2025 Scientific Congress & Expo, October 25–29, 2025, in San Antonio, TX, at booth #619, showcasing its fertility technology solutions.

● USBC will participate in Money20/20 USA, the premier global fintech event, October 26–29, 2025, at the Venetian Resort in Las Vegas, NV. The company will spotlight its tokenized deposits, backed by an OCC-chartered U.S. bank, bridging traditional finance with digital assets.

● SGBX announced a non-binding Letter of Intent (LOI) to acquire Rock Springs Energy Group LLC, advancing its strategy to build an integrated oil and gas business alongside sustainable infrastructure. Based on the LOI execution date of July 28, 2025, the estimated timeline includes: due diligence completion by September 26, 2025, definitive agreement execution by October 26, 2025, and transaction closing by approximately November 25, 2025, pending successful due diligence and regulatory approval.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.